| Subject |
Date
(D/M/Y) |
| This link will open in a new windowRemain Vigilant Against Chikungunya Fever – New Local Case Recorded in Sheung Wan and Latest Situation in Hong Kong |
04-12-2025 |
| This link will open in a new windowBraftovi (encorafenib): Assessing the Potential Risk of Severe Cutaneous Adverse Reactions (Letter to Healthcare Professionals) |
28-11-2025 |
| This link will open in a new windowHand, Foot and Mouth Disease Activity Remains at a High Level |
21-11-2025 |
| This link will open in a new windowRemain Vigilant Against Chikungunya Fever – New Local Case Recorded in Eastern District |
14-11-2025 |
| This link will open in a new windowA Local Case of Chikungunya Fever Living in Tsing Yi |
4-11-2025 |
| This link will open in a new windowThe First Local Case of Chikungunya Fever in Hong Kong |
26-10-2025 |
| This link will open in a new windowRemain Vigilant for Severe Chikungunya Fever and Seasonal Influenza |
22-10-2025 |
| This link will open in a new windowUpdated Situation of Chikungunya Fever |
29-9-2025 |
| This link will open in a new windowAnnouncements on the use of Paracetamol (also known as Acetaminophen) during pregnancy released by the World Health Organization and overseas drug regulatory authorities |
26-9-2025 |
| This link will open in a new windowFDA Responds to Evidence of Possible Association Between Autism and Acetaminophen (Paracetamol) Use During Pregnancy |
23-9-2025 |
| This link will open in a new windowVigilance against Hand, Foot and Mouth Disease |
18-9-2025 |
| This link will open in a new windowHong Kong Enters 2025 Summer Influenza Season |
10-9-2025 |
| This link will open in a new windowTegretol (carbamazepine): use restricted in neonates as concentration of one excipient, propylene glycol, exceeds recommended threshold (Letter to Healthcare Professionals) |
8-9-2025 |
| This link will open in a new windowCaspofungin: new warning against use of polyacrylonitrile-based membranes during continuous renal replacement therapy (Letter to Healthcare Professionals) |
8-9-2025 |
| This link will open in a new windowPolivy (polatuzumab vedotin): New identified risk of severe infusion site extravasation events (Letter to Healthcare Professionals) |
5-9-2025 |
| This link will open in a new windowLipidem® 200mg/ml Emulsion for Infusion (10 x 500 ml): Important information on subvisual agglomerates and the need to use an infusion filter for fat emulsions (Letter to Healthcare Professionals) |
4-9-2025 |
| This link will open in a new windowFDA to recommend additional, earlier MRI monitoring for patients with Alzheimer’s disease taking Leqembi (lecanemab) (Letter to Healthcare Professionals) |
29-8-2025 |
| This link will open in a new windowImportant safety information on CRYSVITA (burosumab) and the risk of severe hypercalcemia in patients with tertiary hyperparathyroidism (Letter to Healthcare Professionals) |
26-8-2025 |
| This link will open in a new windowUpdated Situation of Chikungunya Fever |
14-8-2025 |
| This link will open in a new windowUpdated Situation of Chikungunya Fever and Testing Arrangement |
9-8-2025 |
| This link will open in a new windowUpdated Situation of Chikungunya Fever in Hong Kong |
7-8-2025 |
| This link will open in a new windowBe Vigilant Against Chikungunya Fever After Detection of First Imported Case |
3-8-2025 |
| This link will open in a new windowVigilance Against Chikungunya Fever |
25-7-2025 |
| This link will open in a new windowChange from Pager to Mobile Phone for Emergency Communication with Medical Control Officer |
25-7-2025 |
| This link will open in a new windowAn Outbreak of Chikungunya Fever Reported in Guangdong |
16-7-2025 |
| This link will open in a new windowUpdated Recommendations on Liver Cancer Screening and Nasopharyngeal Cancer Screening |
14-7-2025 |
| This link will open in a new windowGadolinium-based Contrast Agents: Assessing the potential risk of serious adverse reactions, including seizures, encephalopathy, coma and death, with intrathecal use (Letter to Healthcare Professionals) |
27-6-2025 |
| This link will open in a new windowFDA approves required updated warning in labeling of mRNA COVID-19 Vaccines regarding myocarditis and pericarditis following vaccination (Letter to Healthcare Professionals) |
26-6-2025 |
| This link will open in a new windowRelease of the 6th edition of the Interhospital Multi-disciplinary Programme on Antimicrobial ChemoTherapy (IMPACT) Guidelines |
19-6-2025 |
| This link will open in a new windowValproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell▼): updated safety and educational materials to support patient discussion on reproductive risks (Letter to Healthcare Professionals) |
11-6-2025 |
| This link will open in a new windowEuropean Union: PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy (Letter to Healthcare Professionals) |
9-6-2025 |
| This link will open in a new windowEuropean Union: Changes to the use of antibiotic azithromycin (Letter to Healthcare Professionals) |
26-5-2025 |
| This link will open in a new windowFDA requires warning about rare but severe itching after stopping long-term use of oral allergy medicines cetirizine or levocetirizine (Zyrtec, Xyzal, and other trade names) |
19-5-2025 |
| This link will open in a new windowMeasures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines (Letter to Healthcare Professionals) |
9-5-2025 |
| This link will open in a new windowVigilance against upsurge of measles in overseas countries |
29-4-2025 |
| This link will open in a new windowCyclin-dependent kinase inhibitors (abemaciclib, palbociclib and ribociclib) and HMG-CoA reductase inhibitors (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin) (Statins): Assessing the potential risk of rhabdomyolysis due to drug interaction (Letter to Healthcare Professionals) |
25-4-2025 |
| This link will open in a new windowVigilance against Covid-19 in Hong Kong |
25-4-2025 |
| This link will open in a new windowEMA concludes review of weight management medicine Mysimba (naltrexone / bupropion) - Benefits continue to outweigh risks, with new risk minimisation measures and more information to be provided about long-term effect on the heart (Letter to Healthcare Professionals) |
31-3-2025 |
| This link will open in a new windowIsotretinoin: Assessing the potential risk of sacroiliitis (Letter to Healthcare Professionals) |
28-3-2025 |
| This link will open in a new windowOral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban and warfarin): Assessing the potential risk of splenic rupture (Letter to Healthcare Professionals) |
28-3-2025 |
| This link will open in a new windowProlonged-release opioids: Removal of indication for relief of post-operative pain (Letter to Healthcare Professionals) |
13-3-2025 |
| This link will open in a new windowScientific Committee on Vaccine Preventable Diseases interim consensus on the use of respiratory syncytial virus vaccines in Hong Kong |
20-1-2025 |
| This link will open in a new windowArrival of the 2024/25 Influenza Season in Hong Kong |
9-1-2025 |
| This link will open in a new windowVigilance against acute gastroenteritis |
9-1-2025 |
| This link will open in a new windowFDA requires Guillain-Barré Syndrome (GBS) warning in the prescribing information for RSV Vaccines Abrysvo and Arexvy (Letter to Healthcare Professionals) |
8-1-2025 |
| This link will open in a new windowPotential risk of psychiatric withdrawal events with domperidone for stimulation of lactation (Letter to Healthcare Professionals) |
31-12-2024 |
| This link will open in a new windowIlaris (canakinumab): Assessing the potential risk of drug reaction with eosinophilia and systemic symptoms (Letter to Healthcare Professionals) |
20-12-2024 |
| This link will open in a new windowA locally acquired case of dengue fever |
29-11-2024 |
| This link will open in a new windowPromethazine hydrochloride (Phenergan) not to be used in children under 6 (Letter to Healthcare Professionals) |
20-11-2024 |
| This link will open in a new windowTegretol Oral Suspension 2%: Update to the posology, method of administration, and limitation of use in neonates (Letter to Healthcare Professionals) |
13-11-2024 |
| This link will open in a new windowOlanzapine: Assessing the potential risks of syndrome of inappropriate secretion of antidiuretic hormone and hyponatremia (Letter to Healthcare Professionals) |
1-11-2024 |
| This link will open in a new windowGavreto® (pralsetinib): New warning and precaution of severe and fatal infections (Letter to Healthcare Professionals) |
30-10-2024 |
| This link will open in a new windowVigilance against Hand, Foot and Mouth Disease |
9-10-2024 |
| This link will open in a new windowVigilance Against Dengue Fever During And After Holidays |
2-10-2024 |
| This link will open in a new windowSummary Safety Review - Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the potential risks of prolonged or incident diabetic ketoacidosis despite stopping treatment in adult patients with type 2 diabetes (Letter to Healthcare Professionals) |
27-9-2024 |
| This link will open in a new windowPlaquenil® (Hydroxychloroquine sulfate): Risk of major congenital malformations and new risks of phospholipidosis and aggravation of myasthenia gravis symptoms (Letter to Healthcare Professionals) |
20-9-2024 |
| This link will open in a new windowVigilance against Invasive Group B Streptococcus Infection |
14-9-2024 |
| This link will open in a new windowLunsumio (mosunetuzumab): New important identified risk of Hemophagocytic Lymphohistiocytosis (Letter to Healthcare Professionals) |
13-9-2024 |
| This link will open in a new windowEMA recommends measures to minimise the risk of meningioma with medicines containing medroxyprogesterone acetate (Letter to Healthcare Professionals) |
9-9-2024 |
| This link will open in a new windowA locally acquired case of dengue fever |
17-8-2024 |
| This link will open in a new windowWHO declared mpox outbreak as a Public Health Emergency of International Concern |
15-8-2024 |
| This link will open in a new windowAzithromycin and rare risk of cardiovascular death (Letter to Healthcare Professionals) |
2-8-2024 |
| This link will open in a new windowEMA advises about risks of using weight loss medicine Mysimba with opioids (Letter to Healthcare Professionals) |
29-7-2024 |
| This link will open in a new windowThematic Report on Iron Status (Population Health Survey 2020-22) |
16-7-2024 |
| This link will open in a new windowNew recommendations for GLP-1 receptor agonists to minimise risk of aspiration and pneumonia aspiration during general anaesthesia or deep sedation (Letter to Healthcare Professionals) |
15-7-2024 |
| This link will open in a new windowNexavar (sorafenib): Assessing the potential risk of tumour lysis syndrome (Letter to Healthcare Professionals) |
28-6-2024 |
| This link will open in a new windowWarfarin: be alert to the risk of drug interactions with tramadol (Letter to Healthcare Professionals) |
21-6-2024 |
| This link will open in a new windowA probably locally acquired case of dengue fever in 2024 |
19-6-2024 |
| This link will open in a new windowCAR T-cell medicines: PRAC identifies risk of secondary malignancies of T-cell origin (Letter to Healthcare Professionals) |
17-6-2024 |
| This link will open in a new windowVigilance against upsurge of pertussis |
24-5-2024 |
| This link will open in a new windowUpdate on increased Seasonal Influenza Activity in Hong Kong |
2-5-2024 |
| This link will open in a new windowCHMP recommended new contraindications on the co-administration of Reyataz (Atazanavir) with encorafenib and ivosidenib, and with carbamazepine, phenobarbital, and phenytoin (Letter to Healthcare Professionals) |
29-4-2024 |
| This link will open in a new windowThe first local case of dengue fever in 2024 |
26-4-2024 |
| This link will open in a new windowVigilance against B virus infection and addition of the infection to the list of “Other communicable diseases of topical public health concern” |
5-4-2024 |
| This link will open in a new windowEzetrol (ezetimibe) and the risks of drug-induced liver injury and severe cutaneous adverse reactions (Letter to Healthcare Professionals) |
28-3-2024 |
| This link will open in a new windowAmiodarone: Assessing the potential risk of primary graft dysfunction following heart transplantation (Letter to Healthcare Professionals) |
28-3-2024 |
| This link will open in a new windowIbrance (palbociclib): Assessing the potential risk of venous thromboembolism (Letter to Healthcare Professionals) |
28-3-2024 |
| This link will open in a new windowUpdated warnings of faricimab (Vabysmo): retinal vasculitis risk (Letter to Healthcare Professionals) |
21-3-2024 |
| This link will open in a new windowColistin (colistimethate sodium): Assessing the potential risk of pseudo-Bartter syndrome (Letter to Healthcare Professionals) |
1-3-2024 |
| This link will open in a new windowVigilance against upsurge of measles |
29-2-2024 |
| This link will open in a new windowVigilance against ceftriaxone reduced susceptible Neisseria gonorrhoeae infection |
30-1-2024 |
| This link will open in a new windowSafety-related information for the product Mifegyne (Letter to Healthcare Professionals) |
25-1-2024 |
| This link will open in a new window含mifepristone成分藥品安全資訊 (Letter to Healthcare Professionals) (Chinese only) |
24-1-2024 |
| This link will open in a new windowBCMA- and CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapies: risk of T cell malignancies (Letter to Healthcare Professionals) |
24-1-2024 |
| This link will open in a new windowFluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate in the United Kingdom (Letter to Healthcare Professionals) |
23-1-2024 |
| This link will open in a new windowArrival of the 2023/24 Winter Influenza Season in Hong Kong |
11-1-2024 |